We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Alder BioPharmaceuticals on Friday announced that it has submitted the investigational CGRP inhibitor eptinezumab for FDA approval for the prevention of migraine.